Drug Profile
Long acting insulin - Daewoong Pharmaceutical
Alternative Names: DWP 457Latest Information Update: 21 Aug 2023
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 21 Aug 2023 Preclinical development in Diabetes-mellitus is ongoing in South Korea (Daewoong Pharmaceutical pipeline; August 2023).
- 28 Dec 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea
- 23 Nov 2018 Preclinical trials in Diabetes mellitus in South Korea (unspecified route) (Daewoong Pharmaceutical pipeline, November 2018)